Controlled release of Clenbuterol from a hydroxyapatite carrier for the treatment of Alzheimer’s Disease

Biomaterials Research

Research Article

Wei-Ting Kuo¹  Ya-Jyun Liang¹  Yi-Wen Lin¹  Ching-Yun Yang¹  Feng-Huei Lin²  Chih-Hsiang Fang³ 

[1] Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, No. 1, Sec. 4, Roosevelt Rd, 10617, Taipei, Taiwan;Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, No. 1, Sec. 4, Roosevelt Rd, 10617, Taipei, Taiwan;Division of Biomedical Engineering and Nanomedicine Research, National Health Research Institutes, No. 35, Keyan Road, 35053, Zhunan, Miaoli County, Taiwan;National Taiwan University Hospital, No.7, Chung Shan S. Rd., Zhongzheng Dist, 100225, Taipei City, Taiwan;

关键词: Alzheimer’s disease;    Amyloid beta;    Clenbuterol;    Hydroxyapatite;    Controlled release;   

DOI  :  10.1186/s40824-023-00432-4

 received in 2023-06-27, accepted in 2023-09-18,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundAlzheimer’s disease is a neurodegenerative disorder, and Aβ aggregation is considered to be the central process implicated in its pathogenesis. Current treatments are faced by challenges such as serious side effects and reduced drug bioavailability. In this study, we developed a drug delivery system for intramuscular injection that uses cellular activity to achieve constant and long-term drug release.MethodsSynthesized mesoporous hydroxyapatite (SHAP) was prepared via co-precipitation, and hydrophobic surface modification using stearic acid was then used to load clenbuterol by physical absorption, thus creating the drug delivery system. Clenbuterol release was achieved through cellular activity, with macrophage uptake triggering lysosome/endosome disruption, cytoplasmic release, extracellular exocytosis, and subsequent systemic circulation.ResultsWe found that clenbuterol-loaded SHAP enabled sustained release for more than 2 weeks and effectively modulated inflammation, reduced Aβ oligomer-induced toxicity, and prevented Aβ aggregation.ConclusionsOur findings suggest that treatment with clenbuterol loaded in this SHAP delivery system could be a promising strategy for treating Alzheimer’s disease.Graphical Abstract

【 授权许可】

CC BY   
© The Korean Society for Biomaterials 2023

【 图 表 】

Fig. 6

Fig. 1

Fig. 2

12951_2015_155_Article_IEq39.gif

Fig. 2

Fig. 4

12888_2023_5256_Article_IEq1.gif

Fig. 8